Back to CYTR Stock Lookup
Pages: 1 2 »» Last Page

CytRx (CYTR) – Press Releases

Sep 19, 2016 03:43 PM GPM Reminds Investors of the September 23rd Deadline in the Class Action Lawsuit Against CytRx Corporation and Encourages Investors to Contact the Firm
Sep 12, 2016 09:00 AM CytRx to Present Data at the European Society for Medical Oncology 2016 Congress from Aldoxorubicin Plus Ifosfamide/Mesna Combination Clinical Trial
Sep 7, 2016 09:00 AM CytRx Announces the Completion of Enrollment in Its Global Phase 2b Clinical Trial of Aldoxorubicin in Patients with Second-Line Small Cell Lung Cancer
Sep 7, 2016 09:00 AM CytRx Announces the Completion of Enrollment in Its Global Phase 2b Clinical Trial of Aldoxorubicin in Patients with Second-Line Small Cell Lung Cancer
Sep 6, 2016 09:00 AM CytRx to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
Sep 6, 2016 09:00 AM CytRx to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
Aug 26, 2016 10:30 AM Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of CytRx Corporation Investors and Encourages Investors to Contact the Firm
Jul 29, 2016 09:00 AM CytRx Reports Second Quarter 2016 Financial Results
Jul 26, 2016 05:36 PM IMPORTANT SHAREHOLDER NOTICE: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit Against CytRx Corporation and Reminds Investors With Losses to Contact the Firm
Jul 25, 2016 02:45 PM IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces an Investigation of CytRx Corporation and Advises Investors with Losses to Contact the Firm
Jul 25, 2016 01:47 PM Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of CytRx Corporation Investors and Encourages Investors to Contact the Firm
Jul 20, 2016 10:30 AM Glancy Prongay & Murray Commences Investigation on Behalf of CytRx Corporation Investors
Jul 15, 2016 07:30 AM CytRx Corporation Announces Pricing of $20 Million Public Offering of Common Stock and Warrants
Jul 14, 2016 05:43 PM SHAREHOLDER NOTICE: Khang & Khang LLP Announces an Investigation of CytRx Corporation and Reminds Investors with Losses to Contact the Firm
Jul 14, 2016 05:12 PM CytRx Corporation Announces Proposed Public Offering of Common Stock and Warrants
Jul 12, 2016 11:33 AM Investor Alert: Investigation of CytRx Announced by Holzer & Holzer, LLC
Jul 11, 2016 04:03 PM CytRx Announces Initial Results of Phase 3 Trial of Aldoxorubicin in Patients with Second-Line Soft Tissue Sarcoma; Subsequent Analysis to Be Announced Fourth Quarter 2016
Jun 6, 2016 09:00 AM CytRx Presents Updated Aldoxorubicin Clinical Trial Results at the 2016 American Society of Clinical Oncology Annual Meeting
May 31, 2016 09:00 AM CytRx to Present at Jefferies 2016 Global Healthcare Conference
May 11, 2016 09:00 AM CytRx Reports First Quarter 2016 Financial Results
Apr 28, 2016 09:00 AM CytRx to Present at Joseph Gunnar and Co.'s PIONEERS 2016 Investor Conference
Apr 25, 2016 09:00 AM CytRx and PRA Health Sciences Receive Gold Awards for Excellence in Clinical Research as the Strategic Partnership Team of the Year
Apr 20, 2016 09:00 AM CytRx to Present Updated Aldoxorubicin Clinical Trial Data at the American Society of Clinical Oncology Annual Meeting in June 2016
Apr 4, 2016 09:00 AM CytRx Global Pivotal Phase 3 Clinical Trial with Aldoxorubicin Achieves 191 Target Events Triggering Statistical Data Analysis
Mar 22, 2016 09:00 AM CytRx to Present New Data Using Its Proprietary LADRâ„¢ Technology at the 2016 American Association for Cancer Research Annual Meeting
Mar 11, 2016 09:00 AM CytRx Reports 2015 Financial Results
Feb 29, 2016 09:00 AM CytRx to Present at the Cowen & Company's 36th Annual Health Care Conference
Feb 8, 2016 09:00 AM CytRx Secures $40 Million Long-Term Loan Facility
Feb 1, 2016 09:00 AM CytRx to Present at the 18th Annual BIO CEO & Investor Conference
Jan 11, 2016 09:00 AM CytRx Corporation Appoints Olivia Ware as Chief Commercial Officer
Jan 5, 2016 09:00 AM CytRx Announces Settlement of California Stockholder Derivative Lawsuit
Dec 10, 2015 09:00 AM CytRx Announces Settlement of the Consolidated Securities Class Action Lawsuit
Dec 7, 2015 09:00 AM CytRx Nominates Next Clinical Drug Candidate DK049
Dec 3, 2015 09:00 AM CytRx Announces Participation at the 26th Annual Oppenheimer Healthcare Conference
Dec 1, 2015 09:00 AM CytRx Announces the Completion of Enrollment in Pivotal Global Phase 3 Trial Ahead of Schedule
Nov 23, 2015 09:00 AM Aldoxorubicin Continues To Demonstrate Positive Clinical Activity In Phase 2 Glioblastoma Trial
Nov 3, 2015 09:00 AM CytRx Reports 2015 Third Quarter Financial Results
Oct 28, 2015 09:00 AM CytRx to Present Additional Data from its Phase 1b/2 Clinical Trial Combining Aldoxorubicin with Ifosfamide/Mesna at the CTOS 2015 Annual Meeting
Sep 21, 2015 09:00 AM CytRx Announces the Publication of its Positive Global Phase 2b Clinical Trial Results for Soft Tissue Sarcoma in the Peer-Reviewed JAMA Oncology
Sep 3, 2015 09:00 AM CytRx Announces the Presentation of its Phase 2b Clinical Trial Design in Small Cell Lung Cancer at the World Conference on Lung Cancer in Denver, Colorado
Sep 1, 2015 09:00 AM CytRx Announces Participation at FBR & Co. Second Annual Health Conference and Rodman & Renshaw 17th Annual Global Investment Conference
Aug 3, 2015 09:00 AM CytRx Reports 2015 Second Quarter Financial Results
Jul 24, 2015 11:00 AM CytRx Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Jul 21, 2015 08:45 AM CytRx Announces Pricing of Public Offering of 9.1 Million Shares of Common Stock
Jul 20, 2015 04:01 PM CytRx Announces Proposed Public Offering of Common Stock
Jul 9, 2015 10:00 AM Rodman & Renshaw 2015 Annual Global Investment Conference to be held in New York from September 8 to 10, 2015
Jun 30, 2015 09:00 AM CytRx Unveils Novel LADRâ„¢ (Linker Activated Drug Release) Technology Platform
Jun 29, 2015 09:00 AM CytRx Announces Presentation of Interim Phase 2 Data for Aldoxorubicin for HIV-Related Kaposi's Sarcoma
Jun 24, 2015 09:00 AM Cheryl Cohen, Former Medivation Chief Commercial Officer, Joins CytRx Board of Directors
Jun 2, 2015 09:00 AM CytRx Announces Settlement of Stockholder Derivative Lawsuit in Delaware
Pages: 1 2 »» Last Page

Back to CYTR Stock Lookup